Baseline population characteristics of participants who received and did not receive nirmatrelvir–ritonavir before weighting with standardized differences
| Variable | Unweighted population | ||
|---|---|---|---|
| No. (%) of patients* | Standardized difference | ||
| Received nirmatrelvir–ritonavir n = 8876 | Did not receive nirmatrelvir–ritonavir n = 168 669 | ||
| Age, yr | |||
| Mean ± SD | 74.3 ± 16.3 | 52.4 ± 21.0 | 1.17 |
| Median (IQR) | 77 (67–86) | 50 (35–67) | |
| Sex, female | 5261 (59.3) | 106 899 (63.4) | 0.08 |
| No. of vaccine doses | |||
| 0 | 467 (5.3) | 10 434 (6.2) | 0.04 |
| 1 | 87 (1.0) | 1625 (1.0) | < 0.01 |
| 2 | 798 (9.0) | 28 704 (17.0) | 0.24 |
| ≥ 3 | 7524 (84.8) | 127 906 (75.8) | 0.23 |
| Previous SARS-CoV-2 infection | 412 (4.6) | 11 670 (6.9) | 0.10 |
| Time from last vaccine dose, d | |||
| 14–89 | 1453 (16.4) | 17 438 (10.3) | 0.18 |
| 90–179 | 3759 (42.4) | 72 705 (43.1) | 0.02 |
| 180–269 | 2405 (27.1) | 46 190 (27.4) | 0.01 |
| ≥ 270 | 1259 (14.2) | 32 336 (19.2) | 0.13 |
| Ontario COVID-19 Science Advisory Table risk group (11) | |||
| High risk | 3720 (41.9) | 25 499 (15.1) | 0.62 |
| Standard risk | 5156 (58.1) | 143 170 (84.9) | 0.62 |
| Comorbidity | |||
| Chronic respiratory disease | 3128 (35.2) | 40 813 (24.2) | 0.24 |
| Chronic heart disease | 2249 (25.3) | 18 910 (11.2) | 0.37 |
| Diabetes | 2996 (33.8) | 27 954 (16.8) | 0.40 |
| Immune compromised | 1412 (15.9) | 10 102 (6.0) | 0.32 |
| Hypertension | 6071 (68.4) | 54 549 (32.3) | 0.77 |
| Dementia | 2659 (30.0) | 15 714 (9.3) | 0.54 |
| Autoimmune disease | 1150 (13.0) | 8504 (5.0) | 0.28 |
| Chronic kidney disease | 1108 (12.5) | 9867 (5.9) | 0.23 |
| Advanced liver disease | 209 (2.4) | 2110 (1.3) | 0.08 |
| Long-term care resident | 2795 (31.5) | 12 806 (7.6) | 0.63 |
Note: IQR = interquartile range, SD = standard deviation.
↵* Unless specified otherwise.